glp 1 studies 2025 Market Overview: GLP-1 Agonists and the Obesity Market | Blog Mapping the effectiveness and risks

According to the results of the RCT for patients with monogenic obesity ( LEPR or POMC deficiency) and acquired hypothalamic obesity, setmelanotide can reduce body weight and inhibit appetite to a certain extent, and common adverse reactions include injection site reactions, skin hyperpigmentation, nausea, diarrhea, and abdominal pain, with occasional occurrences of sexual adverse reactions, depression, and suicidal ideation [51,52]

25,31 GIP has an augmented effect on insulin secretion, unlike GLP-1, and plays an important role in glucose metabolism in humans

For example, studies on semaglutide 2.4 mg daily reveal an average 8% weight loss in individuals with diabetes over 60 weeks, while those without diabetes see closer to 11%

PMID: 38413012